2016-10-12 10:45
Infant Bacterial Therapeutics AB appoints new CFO
Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co...
2016-08-19 08:00
Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 - June 30 2016
Message from the CEO "In June we announced that the first premature infant had been enrolled and dosed in the Company's Phase ll clinical trial. This...
This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature...
2016-05-26 08:00
IBT's rights issue fully subscribed
Those who have subscribed for shares without subscription rights will be allotted shares according to the principles outlined in the prospectus. Such subscribers...
2016-04-27 20:30
Prospectus relating to IBT's rights issue published
For additional information please contact Staffan Strömberg, CEO, phone: +46 8 410 145 55 Peter Rothschild, chairman, phone: +46 8 410 145 55 Infant...
2016-04-27 08:00
IBT announces fully underwritten SEK 100 million rights issue
Background and reason In late 2013, BioGaia AB (publ) ("BioGaia"), together with IBT's current CEO Staffan Strömberg and Head of R&D...
2016-03-31 09:00
Infant Bacterial Therapeutics receives Rare Pediatric Disease Designation from FDA for drug candidate
Rare Pediatric Disease Designation is intended to encourage development of new drug and biological products for the prevention and treatment of certain...